Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.
Abbisko Therapeutics announced that Merck has exercised its global commercialization option for pimicotinib, a CSF-1R inhibitor, under their licensing agreement. This move, involving an option exercise fee of USD85 million, signifies a deepening collaboration and confidence in pimicotinib’s potential, especially after its successful Phase III trial results for treating tenosynovial giant cell tumor. The agreement could lead to Abbisko receiving up to USD605.5 million in payments, highlighting a significant impact on the company’s financial and industry positioning.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry, focusing on the development of innovative therapies. The company specializes in small molecule inhibitors, with a market focus on oncology and other serious diseases.
YTD Price Performance: 85.65%
Average Trading Volume: 4,501,348
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.8B
Find detailed analytics on 2256 stock on TipRanks’ Stock Analysis page.